Picard Medical Files S-1/A, Nears IPO Launch
Ticker: PMI · Form: S-1/A · Filed: Jul 14, 2025 · CIK: 2030617
Sentiment: neutral
Topics: IPO, S-1/A, Medical Devices, Emerging Growth Company, SEC Filing, Healthcare, Tucson AZ
Related Tickers: PMI
TL;DR
**PMI is gearing up for its IPO, signaling a potential new player in the medical device market; watch for pricing.**
AI Summary
Picard Medical, Inc. (PMI) filed an S-1/A on July 14, 2025, as Amendment No. 4 to its S-1 Registration Statement, indicating its intent to commence a public sale of securities as soon as practicable. The company, classified as a Smaller Reporting Company and an Emerging Growth Company, operates in the Surgical & Medical Instruments & Apparatus sector. While specific revenue and net income figures are not detailed in the provided excerpt, the filing signifies a critical step towards its initial public offering. Key business changes include the formalization of its IPO process, with legal counsel from Winston & Strawn LLP and Sheppard, Mullin, Richter & Hampton LLP. The primary risk highlighted is the inherent uncertainty and regulatory compliance associated with an IPO, as well as the competitive landscape within the medical device industry. PMI's strategic outlook is focused on securing capital through this offering to fund future growth and product development in the medical instruments market. The company's principal executive offices are located at 1992 E Silverlake, Tucson, AZ, 85713, with Patrick NJ Schnegelsberg serving as CEO.
Why It Matters
This S-1/A filing is a crucial step for Picard Medical, Inc. as it moves closer to its initial public offering, potentially opening up new investment opportunities in the medical device sector. For investors, it signals an upcoming chance to gain exposure to an emerging growth company in surgical instruments. Employees could see increased stability and growth prospects, while customers might benefit from expanded product development fueled by new capital. The broader market will gain a new publicly traded entity, intensifying competition within the already dynamic medical instruments and apparatus industry, which could drive innovation and pricing pressures.
Risk Assessment
Risk Level: medium — The risk level is medium because, as an Emerging Growth Company and Smaller Reporting Company, Picard Medical, Inc. faces significant uncertainties inherent in an IPO, including market reception and regulatory hurdles. The filing itself, Amendment No. 4 to Form S-1, suggests ongoing adjustments and complexities in the registration process, which can delay or impact the offering's success. Furthermore, the medical device industry is highly competitive and subject to rapid technological changes and stringent regulatory oversight.
Analyst Insight
Investors should monitor the progress of Picard Medical's IPO, specifically looking for the final offering price and the number of shares being offered. Evaluate the company's full S-1 filing once available for detailed financials, competitive analysis, and management's growth strategy before making any investment decisions.
Financial Highlights
- debt To Equity
- N/A
- revenue
- $N/A
- operating Margin
- N/A%
- total Assets
- $N/A
- total Debt
- $N/A
- net Income
- $N/A
- eps
- $N/A
- gross Margin
- N/A%
- cash Position
- $N/A
- revenue Growth
- +N/A%
Executive Compensation
| Name | Title | Total Compensation |
|---|---|---|
| Patrick NJ Schnegelsberg | Chief Executive Officer | $N/A |
Key Numbers
- 333-286295 — Registration No. (SEC file number for the S-1 registration statement)
- 4 — Amendment No. (Indicates this is the fourth amendment to the S-1 filing)
- 2025-07-14 — Filed Date (Date the S-1/A was filed with the SEC)
- 3841 — SIC Code (Primary Standard Industrial Classification for Surgical & Medical Instruments & Apparatus)
- 520-545-1234 — Business Phone (Primary contact number for Picard Medical, Inc.)
Key Players & Entities
- Picard Medical, Inc. (company) — Registrant for S-1/A filing
- Patrick NJ Schnegelsberg (person) — Chief Executive Officer of Picard Medical, Inc. and agent for service
- Winston & Strawn LLP (company) — Legal counsel for the registrant
- Sheppard, Mullin, Richter & Hampton LLP (company) — Legal counsel for the registrant
- U.S. Securities and Exchange Commission (regulator) — Receiving body for the S-1/A filing
- Michael J. Blankenship (person) — Legal counsel from Winston & Strawn LLP
- Beniamin D. Smolij (person) — Legal counsel from Winston & Strawn LLP
- Richard A. Friedman, Esq. (person) — Legal counsel from Sheppard, Mullin, Richter & Hampton LLP
- Sean F. Reid, Esq. (person) — Legal counsel from Sheppard, Mullin, Richter & Hampton LLP
- Emily Mastoloni Esq. (person) — Legal counsel from Sheppard, Mullin, Richter & Hampton LLP
FAQ
What is the purpose of Picard Medical, Inc.'s S-1/A filing?
Picard Medical, Inc.'s S-1/A filing, Amendment No. 4, is a registration statement under the Securities Act of 1933, indicating the company's intent to offer securities for public sale. It is a crucial step towards its initial public offering (IPO), allowing the company to become publicly traded.
When was Picard Medical, Inc.'s S-1/A filed with the SEC?
Picard Medical, Inc.'s S-1/A was filed with the U.S. Securities and Exchange Commission on July 14, 2025, as indicated by the accession number 0001829126-25-005032.
Who is the CEO of Picard Medical, Inc.?
Patrick NJ Schnegelsberg is the Chief Executive Officer of Picard Medical, Inc. and also serves as the agent for service for the company, with offices at 1992 E Silverlake, Tucson, AZ, 85713.
What industry does Picard Medical, Inc. operate in?
Picard Medical, Inc. operates in the Surgical & Medical Instruments & Apparatus industry, as classified by its Primary Standard Industrial Classification (SIC) Number 3841.
What is Picard Medical, Inc.'s status as a filer?
Picard Medical, Inc. is classified as both a Smaller Reporting Company and an Emerging Growth Company, as indicated by the check marks in the S-1/A filing.
Which law firms are representing Picard Medical, Inc. for its S-1/A filing?
Picard Medical, Inc. is being represented by legal counsel from Winston & Strawn LLP, with Michael J. Blankenship and Beniamin D. Smolij, and Sheppard, Mullin, Richter & Hampton LLP, with Richard A. Friedman, Esq., Sean F. Reid, Esq., and Emily Mastoloni Esq.
What is the business address for Picard Medical, Inc.?
The principal executive offices for Picard Medical, Inc. are located at 1992 E Silverlake, Tucson, AZ, 85713. The business phone number is (520) 545-1234.
What is the proposed date for the sale of securities by Picard Medical, Inc.?
The approximate date of commencement of the proposed sale to the public for Picard Medical, Inc. is stated as 'As soon as practicable after the effective date of this Registration Statement.'
What is the significance of Amendment No. 4 to Form S-1 for Picard Medical, Inc.?
Amendment No. 4 to Form S-1 signifies that Picard Medical, Inc. has made several revisions or updates to its initial S-1 registration statement. This iterative process is common for companies preparing for an IPO, addressing SEC comments or updating company information.
How does Picard Medical, Inc.'s 'Emerging Growth Company' status affect its regulatory compliance?
As an 'Emerging Growth Company,' Picard Medical, Inc. may be eligible for certain scaled disclosure requirements and exemptions from various reporting and governance requirements, as provided pursuant to Section 7(a)(2)(B) of the Securities Act, which can reduce the burden of public company compliance.
Risk Factors
- IPO Uncertainty and Compliance [high — regulatory]: The company faces inherent uncertainties and regulatory compliance requirements associated with its Initial Public Offering (IPO). This includes navigating the complex legal and financial processes necessary for a public listing, which can be time-consuming and resource-intensive.
- Competitive Medical Device Landscape [high — market]: Picard Medical operates within the highly competitive Surgical & Medical Instruments & Apparatus sector. Success will depend on its ability to differentiate its products and gain market share against established players and emerging innovators.
- Product Development and Innovation [medium — operational]: The company's strategic outlook focuses on securing capital for future growth and product development. Failure to innovate or bring new products to market effectively could hinder its competitive position and long-term success.
Industry Context
Picard Medical operates in the Surgical & Medical Instruments & Apparatus sector, a dynamic and competitive industry. This market is characterized by continuous innovation, stringent regulatory oversight, and a significant presence of both established global players and specialized niche companies. Growth in this sector is often driven by advancements in medical technology, an aging global population, and increasing demand for minimally invasive procedures.
Regulatory Implications
As a medical device company pursuing an IPO, PMI is subject to rigorous regulatory scrutiny from bodies like the FDA. Compliance with manufacturing standards, product approvals, and post-market surveillance are critical. The IPO process itself involves extensive SEC regulations and disclosure requirements, demanding transparency and adherence to securities laws.
What Investors Should Do
- Monitor SEC Filings for Financial Details
- Evaluate Competitive Positioning
- Assess Management Team and Strategy
Key Dates
- 2025-07-14: Filing of S-1/A Amendment No. 4 — Indicates the company is progressing through the IPO process and providing updated information to the SEC.
- 2025-07-11: Submission Date — The date the filing was officially submitted to the SEC.
Glossary
- S-1/A
- An amendment to a registration statement filed with the SEC, used by companies planning to go public to provide updated or corrected information. (This is the core document for Picard Medical's IPO, detailing its business, financials, and risks.)
- Smaller Reporting Company
- A classification by the SEC for companies with a public float of less than $250 million and annual revenues of less than $100 million. (This classification may allow PMI to benefit from certain scaled disclosure requirements, simplifying its reporting obligations.)
- Emerging Growth Company
- A company with total annual gross revenues of less than $1.235 billion during its most recently completed fiscal year, which can take advantage of extended transition periods for complying with new or revised accounting standards. (PMI's status as an EGC provides flexibility in adopting new accounting rules, potentially delaying implementation costs and complexities.)
- SIC Code 3841
- Standard Industrial Classification code for Surgical & Medical Instruments & Apparatus. (This code categorizes Picard Medical's primary business operations within the medical device industry.)
Year-Over-Year Comparison
As this is Amendment No. 4 to the S-1 filing, it represents a progression in the IPO process rather than a direct comparison of operational performance to a prior year's financial statements. Key changes likely involve updated risk factors, refined business descriptions, and potentially revised legal or underwriting information as the company moves closer to its public offering. Specific financial metrics and their year-over-year changes are not available in this excerpt.
Filing Details
This Form S-1/A (Form S-1/A) was filed with the SEC on July 14, 2025 by Patrick NJ Schnegelsberg regarding Picard Medical, Inc. (PMI).